← All indications
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Drugs by status
Approved for this indication (4)
Phase 3 trials (5)
Phase 2 trials (35)
- anlotinib
- atezolizumab
- selinexor
- durvalumab
- gemcitabine
- paclitaxel
- apalutamide
- pembrolizumab
- lurtotecan
- pemetrexed
- carboplatin
- rrx-001
- sagopilone
- arsenic trioxide
- temozolomide
- tivantinib
- enoxaparin
- veliparib
- vinflunine
- vosaroxin
- bi-2536
- talabostat
- pomalidomide
- r-16341
- sintilimab
- Tafolecimab
- toripalimab
- hlx10
- bintrafusp alfa
- cetrelimab
- +5 more
Organizations
Organization Involved with Phase 3 Indications (14)
- Celgene
- Imclone
- Merck KGaA
- Chong Kun Dang Pharmaceutical
- EpicentRx, Inc.
- National Cancer Institute (NCI)
- Cornell University
- NRG Oncology
- Spanish Lung Cancer Group
- Groupe Francais De Pneumo-Cancerologie
- Chonnam National University
- EORTC Lung Cancer Cooperative Group
- Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung
- Johnson and Johnson
Organization Involved with Phase 2 Indications (61)
- Zenith Epigenetics
- Cephalon
- Bristol-Myers Squibb
- OSI Pharmaceuticals
- Roche
- Advaxis, Inc.
- Astellas
- AstraZeneca
- Merck
- Eli Lilly
- Genentech
- Sanofi
- Novartis
- Bayer
- GlaxoSmithKline
- Tarveda Therapeutics
- Sunesis Pharmaceuticals
- Teva
- Threshold Pharmaceuticals
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- United States Army
- Cancer and Leukemia Group B (CALGB)
- Harvard University
- ECOG-ACRIN Cancer Research Group
- Emory University
- University of Washington
- Gynecologic Oncology Group
- Istituto Oncologico Veneto IRCCS
- James Graham Brown Cancer Center
- +31 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (2)